A Phase 2 interventional study of Ipilimumab/ Nivolumab and SBRT + Ipilimumab/Nivolumab in Metastatic Renal Cell Carcinoma, sponsored by Ontario Clinical Oncology Group (OCOG). Completed at 7 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Carcinoma, Renal Cell with a site in Canada — 10 open to participants now, 29 under way, 10 of them phase 3. Carcinoma, Renal Cell · Canada.
Among the 160 studies in Carcinoma, Renal Cell with a site in Canada, this one is the 87th largest by enrollment of the 142 interventional ones that give a count, is one of 17 that started in 2020, is one of 37 in phase 2, and was the 116th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →10 of the 160 studies in Carcinoma, Renal Cell with a site in Canada are open now. Recruiting first, the newest first:
Canadian Cancer Trials Group · Sites in Canada
Ages 15+
Merck Sharp & Dohme LLC · Sites in Canada, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, Argentina and 17 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, France and 2 more countries
Ages 18+
Derek W. Cool · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 56 · Phase 3 46
First in 1992; this study’s year is marked. 17 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 128 across the 142 interventional studies, 102 across the 11 observational. Of the 119 that completed or were terminated, 57 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 160 have an industry lead sponsor. The 10 most frequent:
Ontario Clinical Oncology Group (OCOG) is the lead sponsor of 56 studies on the registry; 4 are open to participants now.
Ontario Clinical Oncology Group (OCOG) has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Renal Cell with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
| NCT06764771Bristol-Myers SquibbA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | 2027-10-15 |
| NCT03747133University Health Network, TorontoSABR for Renal Tumors | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 160 studies in Carcinoma, Renal Cell with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
This is a multi-centre, open label, phase II randomized clinical trial evaluating SBRT as upfront cytoreductive therapy to the primary renal mass along with combination I/N therapy in patients with intermediate/poor risk mRCC who are not candidates for cytoreductive nephrectomy. Eligible and consenting, newly diagnosed and histologically confirmed intermediate/poor risk mRCC patients based on IMDC criteria with primary disease in-situ will be randomized in a 2:1 fashion to either induction I/N followed by SBRT prior to the second cycle (experimental arm) versus I/N alone (standard arm). Patients will be stratified based on IMDC criteria (intermediate 1-2 versus poor 3-6).
During treatment (standard and experimental arm) participants will be assessed for radiation toxicity and the occurrence of adverse events. Following treatment, participants will be assessed at a clinic visit every 3 months, for a period of 1 year. Progression free survival will be assessed by CT scan (chest; abdomen and pelvis), which is performed after the final I/N treatment and every 3 months as per standard of care. Participants will be followed for one additional year, seen at 18 and 24 months to assess survival. The planned sample size is 78 study participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
Drug: Ipilimumab/ Nivolumab
induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
Radiation: SBRT + Ipilimumab/Nivolumab
induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
Also known as: Yervoy/Opdivo
SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Progression free survival (PFS)
The primary outcome of this study is the hazard ratio for progression-free survival (PFS), defined from the date of randomization until the date of progression (PFS truncated at subsequent systemic therapy) as determined by RECIST 1.1, or death due to any cause, whichever comes first. All attempts will be made to follow-up patients for the primary outcome measure for at least one year, even if a patient stops treatment. Patients who do not have a primary outcome event at the time of analysis will be censored on the last date the patient can be confirmed as alive and progression-free.
Time frame: 2 years
Subject safety
Incidence and attribution of deaths
Time frame: Date of randomization until 1year post treatment
Overall Survival
• Overall survival, defined from the date of randomization to the date of death due to any cause. Patients with no known death date at the time of analysis will be censored on the last date they are confirmed alive.
Time frame: 2 years
Objective response rate
• Objective response rate, which is defined as the proportion of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) using the RECIST 1.1 criteria.
Time frame: 1 year
Quality of Life: EORTC QLQ-C30 questionnaire
• Quality of life, which will be evaluated using the EORTC QLQ-C30 questionnaire.
Time frame: 1 year
Subject safety
Number of Adverse Events and Serious Adverse Events using NCI CTCAE v5.0
Time frame: 1 Year
Ipilimumab/ Nivolumab drug tolerability
Ipilimumab/Nivolumab treatment discontinuation rates
Time frame: From the date of randomization until date of first documented disease progression up to 1 year.
Ipilimumab/ Nivolumab drug tolerability
Number of doses of Ipilimumab/Nivolumab combination treatment
Time frame: From the date of randomization until date of first documented disease progression, up to 1 year.
Ipilimumab/ Nivolumab drug tolerability
Number of Nivolumab maintenance doses
Time frame: From the date of randomization until date of first documented disease progression, up to 1 year.
Ipilimumab/ Nivolumab drug tolerability
Time to treatment discontinuation from the date of randomization
Time frame: From the date of randomization until date of first documented disease progression, up to 1 year.
Exploratory Outcomes: Evaluation of baseline and changes during treatment in blood immune signatures
Changes in blood immune signatures through interrogation of circulating blood biomarkers.
Time frame: 1 year
Exploratory Outcomes: Evaluation of baseline and changes during treatment in stool microbiome
Changes in stool microbiome using 16S RNA.
Time frame: 1 year
Correlation with blood or stool immune signatures
Tumor tissue analysis using immunohistochemistry
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Apr 2026, 74 months.
Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 74 months is above that.
Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ontario Clinical Oncology Group (OCOG)